Recursion Pharmaceuticals Stock News

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Call Participants Andrew Pucher Presentation Andrew Pucher Welcome to this afternoon session with Recursion. My name is Andrew Pucher.

The real artificial intelligence (AI) opportunity isn't hiding in the obvious names that dominate headlines. It's emerging in industries that have barely changed in decades -- and are now primed for AI-driven disruption.

Prosper Junior Bakiny has positions in Nvidia and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia.

Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Citi 2025 BioPharma Back to School Conference — Wednesday, September 3, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference — Monday, September ...

Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry. One way to do that is to buy shares of the leading companies in the field, such as Nvidia.

It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape even more in the foreseeable future.

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX 3.35%) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Market darlings like Nvidia and Palantir Technologies are still solid investment prospects to be sure. After several years of big gains, however, these crowded trades are starting to show signs of age.